Activity (functional)
|
|
NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.
|
ChEMBL.
|
22096101
|
CC50 (functional)
|
> 10 uM
|
Huh7 cytotoxicity for Pf inhibitors
|
Novartis-GNF Malaria Box.
|
No reference
|
CC50 |
> 10 uM
|
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
|
ChEMBL.
|
18579783
|
EC50 (functional)
|
= 0.2311 uM
|
PF proliferation inhibition 3D7
|
Novartis-GNF Malaria Box.
|
No reference
|
EC50 (functional)
|
= 0.2311 uM
|
NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay
|
ChEMBL.
|
18579783
|
EC50 (functional)
|
= 0.424 uM
|
W2 Pf proliferation inhibition
|
Novartis-GNF Malaria Box.
|
No reference
|
EC50 (functional)
|
= 0.424 uM
|
NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay
|
ChEMBL.
|
18579783
|
IFI promiscuity index |
= 0.14286
|
IFI promiscuity index
|
Novartis-GNF Malaria Box.
|
No reference
|
Inhibition (functional)
|
= -0.54 %
|
ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro
|
ChEMBL.
|
No reference
|
Inhibition (functional)
|
= 0 %
|
GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM
|
ChEMBL.
|
20485427
|
Inhibition (functional)
|
= 1.2 %
|
ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro
|
ChEMBL.
|
No reference
|
Inhibition (functional)
|
= 2 %
|
GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM
|
ChEMBL.
|
20485427
|
Inhibition (functional)
|
= 2.48 %
|
ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro
|
ChEMBL.
|
No reference
|
Inhibition (functional)
|
= 7 %
|
GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM.
|
ChEMBL.
|
20485427
|
Inhibition (functional)
|
= 85 %
|
GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM
|
ChEMBL.
|
20485427
|
Inhibition frequency index (IFI) (functional)
|
= 2.99
|
Inhibition Frequency Index (IFI)
|
GSK.
|
20485427
|
Percent growth inhibition (functional)
|
= -3 %
|
Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM)
|
GSK.
|
20485427
|
Percent growth inhibition (functional)
|
= 2 %
|
Percent inhibition of P. falciparum Dd2 growth (at 2 uM)
|
GSK.
|
20485427
|
Percent growth inhibition (functional)
|
= 7 %
|
Percent inhibition of HepG2 growth (at 10 uM)
|
GSK.
|
20485427
|
Percent growth inhibition (functional)
|
= 85 %
|
Percent inhibition of P. falciparum 3D7 growth (at 2 uM)
|
GSK.
|
20485427
|
XC50 (functional)
|
= 5.9
|
XC50 determination of P. falciparum 3D7 growth
|
GSK.
|
20485427
|
XC50 (functional)
|
= 1.24504 uM
|
GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth.
|
ChEMBL.
|
20485427
|